Funder: METAvivor
Due Dates: March 16, 2026 (LOI, 2026 cycle) | March 11, 2025 (LOI, 2025 cycle)
Funding Amounts: Up to $450,000 total over three years per award.
Summary: Supports established investigators conducting basic, translational, or clinical research addressing key barriers in metastatic breast cancer (MBC).